New Insights Into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.

Mason R. Preston
Current atherosclerosis reports, 2019

Abstract

Purpose of review

Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk. Genetic and epidemiologic studies have shown that elevated fasting TG levels are associated with incident cardiovascular events. At effective doses, omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower TG levels but may have additional atheroprotective properties compared to other TG-lowering therapies such as niacin and fibrates. The purpose of this review is to evaluate mechanisms related to the potential benefits of omega-3 fatty acids in atherothrombotic disease.

Recent findings

Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day). A large randomized trial with a prescription EPA-only formulation was shown to reduce a composite of cardiovascular events by 25% in statin-treated patients with established cardiovascular disease or diabetes and other CV risk factors. EPA and DHA have distinct tissue distributions as well as disparate effects on membrane structure and lipid dynamics, rates of lipid oxidation, and signal transduction pathways. Compared to other TG-lowering therapies, EPA has been found to inhibit cholesterol crystal formation, inflammation, and oxidative modification of atherogenic lipoprotein particles. The anti-inflammatory and endothelial benefits of EPA are enhanced in combination with a statin. Omega-3 fatty acids like EPA only at a pharmacologic dose reduce fasting TG and interfere with mechanisms of atherosclerosis that results in reduced cardiovascular events. Additional mechanistic trials will provide further insights into their role in reducing cardiovascular risk in subjects with well-managed LDL-C but elevated TG levels.

Keywords

Atherosclerosis; Cholesterol; Eicosapentaenoic; Lipoproteins; Omega-3 fatty acids; Triglycerides.

PMID:30637567
DOI:10.1007/s11883-019-0762-1
PMCID (Free PMC Article):PMC6330561
Category:Cardiovascular Support

The best supplements with Omega-3 Acids in Cardiovascular Support category:

Articles similar to "New Insights Into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease."

  • The significance of Omega-3 Acids for Cardiovascular Support: Marine OMEGA-3 Fatty Acids in the Prevention of Cardiovascular Disease. (Omega-6 (ω6) and omega-3 (ω3) fatty acids are two classes of dietary polyunsaturated fatty acids derived from linoleic acid (18:2ω6) and Alpha-Linolenic Acid (18:3ω3), respectively...)
  • The role of Omega-3 Acids in Cardiovascular Support: Omega-3 Fatty Acids and Cardiovascular Disease. (Cardioceuticals are nutritional supplements that contain all the essential nutrients including vitamins, minerals, omega-3-fatty acids and other antioxidants like a-lipoic acid and coenzyme Q10 in the right proportion that provide all round protection to the heart by reducing the most common risks associated with the cardiovascular disease including high low-density lipoprotein cholesterol and triglyceride levels and factors that contribute to coagulation of blood...)
  • The significance of Omega-3 Acids for Cardiovascular Support: Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. (Context: Increased dietary intake of marine omega-3 fatty acids is associated with prolonged survival in patients with coronary heart disease... Among this cohort of patients with coronary artery disease, there was an inverse relationship between baseline blood levels of marine omega-3 fatty acids and the rate of telomere shortening over 5 years.)

Previous article

Health Benefits of Docosahexaenoic Acid (DHA).

Next article

Effect of Eicosapentaenoic Acid (EPA) Supplementation on Cardiovascular Markers in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial.